Peptide Regulation in 2026: FDA Rules, GLP-1 Crackdowns, and What's Next

The peptide regulatory landscape in the United States has undergone dramatic shifts between 2024 and 2026. Compounded GLP-1 medications like semaglutide and tirzepatide face strict enforcement following the resolution of national shortages, while research peptides such as BPC-157 and TB-500 are moving through a formal FDA review process that could restore legal compounding access. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet July 23-24, 2026 to evaluate seven peptides for potential inclusion on the 503A Bulks List—the first formal pathway toward regulated access since 19 peptides were restricted in late 2023.

This guide breaks down the current regulatory framework, explains what changed under the Kennedy administration, and clarifies what patients and researchers can legally access today.

This content is for informational purposes only and is not medical advice. Consult a healthcare provider before using any peptides.

What Is the FDA's Peptide Category System?

Understanding peptide regulation requires knowing how the FDA classifies compounding pharmacies and the substances they can use. Two distinct regulatory frameworks govern peptide compounding in the United States.

503A vs 503B Compounding Pharmacies

Section 503A pharmacies are traditional state-licensed compounding pharmacies that prepare medications based on individual patient prescriptions from licensed practitioners. These pharmacies compound patient-specific formulations and cannot mass-produce medications for general distribution.

Section 503B outsourcing facilities compound medications in larger quantities without requiring patient-specific prescriptions. These facilities operate under stricter FDA oversight and must register with the agency, but they can supply hospitals, clinics, and healthcare systems with compounded drugs.

The distinction matters because each type faces different rules about which bulk drug substances they can use.

Category 1, 2, and 3 Explained

The FDA maintains a category system for bulk drug substances used in compounding:

• Category 1: Substances the FDA has evaluated and determined can be used in compounding, subject to applicable conditions. Compounding pharmacies may source and compound with these substances.

• Category 2: Substances the FDA has evaluated and determined present significant safety or quality concerns. A Category 2 designation effectively prohibits compounding pharmacies from using the substance.

• Category 3: Substances lacking sufficient documentation for FDA evaluation. These remain in regulatory limbo pending additional information.

This category system became central to peptide access when the FDA moved 19 widely-used peptides from Category 1 to Category 2 in late 2023.

What Happened to Compounded GLP-1 Medications?

The GLP-1 receptor agonist market—dominated by brand-name drugs like Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide)—experienced severe shortages beginning in 2022. These shortages created a legal opening for compounding pharmacies to produce semaglutide and tirzepatide under FDA enforcement discretion.

That window has now closed.

Shortage Resolution Timeline

The FDA officially resolved both major GLP-1 shortages:

• Tirzepatide: Shortage ended December 2024
• Semaglutide: Shortage ended February 2025

With shortages resolved, the legal basis for compounding "essentially copies" of these commercially available drugs disappeared.

Enforcement Deadlines

The FDA established phased enforcement deadlines for compounders to wind down operations:

• Tirzepatide (503B outsourcing facilities): March 19, 2025
• Semaglutide (503B outsourcing facilities): May 22, 2025

As of mid-2025, compounding of essentially identical copies of either medication is no longer legally permissible for 503A or 503B entities.

Safety Concerns Driving Enforcement

The FDA's aggressive enforcement stance reflects documented safety issues. According to FDA adverse event data, by July 31, 2025, the agency had logged over 1,150 reports tied to compounded semaglutide and tirzepatide, including 17 deaths. This represented more than a fourfold increase over all compounded drug adverse events recorded in fiscal year 2022.

A Brookings Institution report published in April 2025 identified that three Chinese firms supplying roughly 20% of semaglutide API used in U.S. compounding had never been inspected by the FDA, raising questions about quality assurance in the compounded drug supply chain.

Warning Letters and Telehealth Crackdown

On March 3, 2026, the FDA sent 30 warning letters to telehealth companies marketing compounded semaglutide and tirzepatide. The primary violation: claiming compounded versions are the "same as" or "equivalent to" FDA-approved branded drugs.

Six days later, Hims & Hers struck a deal with Novo Nordisk to stop marketing compounded GLP-1s and transition to selling branded products instead.

In total, the FDA issued over 80 warning letters to telehealth companies for allegedly misleading marketing of compounded GLP-1 products in the twelve months ending March 2026.

Which Peptides Were Banned in 2023?

In late 2023, the FDA moved 19 widely-used peptides from Category 1 to Category 2 after identifying what the agency described as "significant, unresolved patient safety risks." This effectively ended licensed compounding pharmacies' ability to prepare and dispense these compounds.

The 19 Restricted Peptides

The Category 2 list included peptides commonly used in regenerative medicine, anti-aging protocols, and performance optimization:

The FDA cited lack of adequate safety data, quality control concerns, and potential for adverse effects as reasons for the restrictions. Critics—including clinicians, compounding pharmacists, and members of Congress—argued the ban was regulatory overreach that pushed patients toward unregulated grey-market sources.

What Is Changing Under the Kennedy Administration?

Robert F. Kennedy Jr. was confirmed as Secretary of Health and Human Services in February 2025, representing what observers describe as the most significant reset of federal health priorities in two decades. Kennedy's approach to peptide regulation differs markedly from his predecessors.

The Joe Rogan Announcement

On February 27, 2026, during Episode #2461 of The Joe Rogan Experience, Secretary Kennedy announced that approximately 14 of the 19 peptides restricted under Category 2 would be moved back to Category 1, restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription.

Kennedy acknowledged that the restrictions "created the grey market," pushing patients to unregulated sources with no quality oversight.

April 2026: Official FDA Action

On April 15, 2026, the FDA published its most consequential 503A category revision in years. In a single update, twelve peptide-based bulk drug substances were removed from Category 2 due to withdrawal of nominations:

• BPC-157 (free base and acetate)
• TB-500 (free base and acetate)
• MOTS-c (free base and acetate)
• GHK-Cu (injectable)
• Melanotan II
• Semax
• PEG-MGF
• KPV (free base and acetate)
• Epitalon
• Emideltide (DSIP)

What This Does—and Doesn't—Mean

Important clarification: Removal from Category 2 does not automatically confer Category 1 status. Each substance requires individual Pharmacy Compounding Advisory Committee (PCAC) review before reclassification.

These peptides remain:

• Not FDA-approved drugs
• Not lawful dietary supplement ingredients
• Not eligible for routine compounding until formal rulemaking concludes

The regulatory status persists, making it technically illegal to produce these peptides for human consumption until the conclusion of formal rulemaking—a process that takes 12-18 months minimum.

What Will the July 2026 PCAC Meeting Decide?

The FDA's Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 at the FDA White Oak Campus in Silver Spring, Maryland. This meeting represents the first formal step toward potential regulatory clarity for research peptides.

Meeting Details

• Dates: July 23-24, 2026
• Time: 8:00 a.m. to 4:30 p.m. ET (Day 1), 8:00 a.m. to 3:50 p.m. ET (Day 2)
• Location: FDA White Oak Campus, Building 31, Room 1503 (The Great Room)
• Format: Hybrid (in-person and virtual participation available)

Peptides Under Review

July 23, 2026:

July 24, 2026:

Public Comment Deadlines

• July 9, 2026: Comments provided to the Committee for review
• July 22, 2026 (11:59 p.m. ET): Final deadline for written comments
• June 30, 2026: Deadline to register for oral presentations
• Docket Number: FDA-2025-N-6895

What Happens After the Meeting?

The PCAC's recommendation is non-binding. Even if the committee recommends adding these peptides to the 503A Category 1 list, and even if the FDA agrees, notice-and-comment rulemaking is still required. Under standard timelines, this process can take more than a year.

The FDA has also announced a second PCAC meeting before the end of February 2027 to review five additional peptides: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and PEG-MGF.

Are Research Peptides Legal to Buy?

Research peptides occupy a complex legal space that many consumers misunderstand. The answer depends on intent, labeling, and source.

The "Research Use Only" Grey Market

Most peptides discussed in wellness and sports contexts are sold online labeled "for research use only" or "not for human consumption." This labeling is a legal fiction that allows vendors to sell unapproved compounds while technically complying with regulations prohibiting sale for human use.

Key points:

• Most peptides are not scheduled controlled substances
• They are not FDA-approved for human use
• They cannot legally be sold as dietary supplements
• Selling them explicitly for human use is prohibited
• Possession and purchase for legitimate research purposes generally remains lawful
• Injecting "research-only" products is technically illegal

Enforcement Actions Intensifying

The Department of Justice prosecuted Tailor Made Compounding LLC for distributing unapproved peptides, including BPC-157, forcing the company to forfeit $1.79 million. This case signals increased federal attention to the peptide supply chain.

State-level enforcement is also accelerating. Ohio's state medical and pharmacy boards initiated investigations into multiple medical spas after receiving complaints and reports of adverse patient outcomes linked to non-FDA-approved peptides sourced from unlicensed international suppliers.

Quality and Safety Concerns

Grey-market peptides carry significant risks:

• No quality guarantees: Independent testing has repeatedly uncovered incorrect dosing, contamination, and completely wrong compounds in vials from unregulated suppliers
• No sterility assurance: Injectable products require strict sterile manufacturing that grey-market vendors cannot verify
• No medical oversight: Without physician involvement, patients cannot monitor for adverse effects or drug interactions
• No recourse: Products from unregulated sources offer no legal protections if something goes wrong

The closure of PeptideSciences.com in early March 2026—one of the highest-traffic grey-market suppliers in the United States—highlighted the precarious nature of this market.

What About GLP-1s From Compounding Pharmacies Now?

Despite the crackdown, limited pathways remain for compounded GLP-1 access.

503A Pharmacy Options

Traditional compounding pharmacies (503A) may still fill individual prescriptions with documented clinical justification. The FDA has stated it will not take enforcement action if compounders fill "four or fewer prescriptions of that compounded drug product during a calendar month," provided:

• The prescriber documents significant differences for individual patients
• The compounded product is not merely a copy of the commercial drug
• The pharmacy meets all other regulatory requirements

Example: A compounder could combine semaglutide with vitamin B12 if strengths stay within 10% of approved products and the prescriber documents medical justification for the combination.

503B Outsourcing Facilities

Outsourcing facilities face much stricter restrictions. They cannot legally produce semaglutide or tirzepatide for general distribution in 2026 unless:

• The drug is on the FDA's shortage list (neither currently is)
• The substance is on the 503B bulks list (proposed rule excludes both)

On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no clinical need for outsourcing facilities to compound these drugs from bulk API. Comments are due by June 29, 2026.

Still in Shortage

Liraglutide (Victoza/Saxenda) remained listed as in shortage as of early 2026, potentially allowing continued compounding under shortage provisions.

Key Takeaways

• GLP-1 compounding is largely prohibited: With tirzepatide and semaglutide shortages resolved, enforcement is active. Only limited 503A patient-specific compounding with clinical justification remains permissible.

• Research peptides are in regulatory transition: 12 peptides were removed from Category 2 in April 2026, but this does not make them legal to compound—formal PCAC review and rulemaking are required.

• The July 2026 PCAC meeting is pivotal: Seven peptides including BPC-157 and TB-500 will be formally evaluated for potential 503A inclusion.

• Final rulemaking takes 12-18+ months: Even favorable PCAC recommendations don't immediately change legal status.

• Grey-market peptides remain risky: Unregulated products carry quality, safety, and legal risks that legitimate compounding pathways would address.

• State enforcement is increasing: Multiple states are investigating medical spas and clinics using non-FDA-approved peptide sources.

Frequently Asked Questions

Can I still get compounded semaglutide in 2026?

Limited access remains through 503A pharmacies for patient-specific prescriptions with documented clinical need. The prescriber must justify why a compounded formulation—such as a different strength or combination product—is medically necessary for the individual patient. Mass compounding and general distribution of semaglutide copies are prohibited.

Is BPC-157 legal in 2026?

BPC-157 was removed from FDA Category 2 in April 2026, but it is not yet legal to compound. The peptide will be formally reviewed by the PCAC in July 2026. If recommended for the 503A bulks list and approved through rulemaking, compounding pharmacies could legally prepare it—but this process takes 12-18+ months. Currently, BPC-157 remains an unapproved drug that cannot be legally produced for human consumption.

When will peptides become available from compounding pharmacies again?

The earliest regulatory clarity comes from the July 2026 PCAC meeting. If the committee recommends adding peptides to the 503A list and the FDA agrees, notice-and-comment rulemaking follows. Optimistically, some peptides could become legally compoundable by late 2027 or early 2028. A second PCAC meeting covering additional peptides is scheduled before February 2027.

Are grey-market "research" peptides safe?

No reliable safety assurances exist for grey-market peptides. Independent testing has found incorrect dosing, contamination, and wrong compounds in products from unregulated vendors. Without verified sterility, proper storage, and quality testing, injectable products pose infection and adverse reaction risks. The legal status also remains precarious—injecting products labeled "not for human consumption" is technically illegal.

What is the difference between 503A and 503B pharmacies?

503A pharmacies compound patient-specific prescriptions from licensed practitioners. They operate under state pharmacy boards with FDA oversight for certain requirements. 503B outsourcing facilities compound larger quantities without patient-specific prescriptions and operate under direct FDA oversight. 503B facilities can supply hospitals and clinics but face stricter rules about which bulk substances they can use.

Conclusion

The peptide regulatory environment in 2026 represents a period of significant transition. GLP-1 compounding faces strict enforcement following shortage resolution, while research peptides are moving through a formal review process that could restore legal access through licensed compounding pharmacies.

The July 2026 PCAC meeting marks a critical milestone—the first formal evaluation of peptides like BPC-157 and TB-500 since they were restricted in 2023. However, patients and practitioners should understand that favorable recommendations don't immediately change legal status. Formal rulemaking requires 12-18+ months minimum.

For now, grey-market peptides remain the only accessible option for many compounds, but this pathway carries documented quality, safety, and legal risks. As the regulatory framework evolves, the safest approach is working with licensed healthcare providers who can navigate the complex landscape of what's legally available and clinically appropriate.

We'll continue updating this guide as regulatory developments unfold.

---

Last updated: May 2026

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before using any peptides or medications.

Sources

• FDA: Pharmacy Compounding Advisory Committee Meeting July 23-24, 2026
• FDA: Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
• FDA: Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List
• Federal Register: Pharmacy Compounding Advisory Committee Notice of Meeting
• NCPA: FDA Ends Compounding Discretion for Tirzepatide
• USADA: BPC-157 Experimental Peptide Creates Risk for Athletes
• OPSS: BPC-157 Prohibited Peptide and Unapproved Drug
• Frier Levitt: Regulatory Status of Peptide Compounding in 2025
• Pharmacy Times: FDA Moves to Permanently Close Door on Compounded GLP-1s